University at Buffalo biophysicists find L-arginine blocks Alzheimer's-linked fibril formation
Updated
Updated · SciTechDaily · May 1
University at Buffalo biophysicists find L-arginine blocks Alzheimer's-linked fibril formation
6 articles · Updated · SciTechDaily · May 1
In a Nature Communications study, Priya Banerjee's team found Tau fibrils begin at protein droplet surfaces, while L-arginine kept droplets liquid-like and functional.
The researchers said the molecule reduced fibril formation without disrupting droplets' role in stabilising and assembling microtubules inside cells.
The work suggests droplet formation and fibril formation are separable, offering a potential route to therapies targeting toxic Tau buildup in Alzheimer's while preserving normal cellular activity.
If blocking tau fibril formation preserves brain function, could this approach delay memory loss, or are there hidden drawbacks yet to be uncovered?
Could stabilizing protein droplets with L-arginine revolutionize Alzheimer's treatment, or will unexpected side effects like accelerated aging emerge?
L-Arginine Stabilizes Tau Protein Condensates to Prevent Alzheimer's-Linked Amyloid Fibril Formation
Overview
Recent research has revealed that L-arginine can enter Tau protein condensates in brain cells and stabilize them through specific molecular interactions, preventing these condensates from turning into toxic amyloid fibrils while preserving their normal function. Additionally, studies in animal models show that oral L-arginine reduces harmful amyloid-beta plaque buildup and improves brain health. This dual action makes L-arginine a promising candidate for Alzheimer's treatment, with Phase II clinical trials expected within 2 to 4 years. Moreover, its mechanism may also apply to Parkinson's disease, which involves similar protein aggregation processes. However, determining safe and effective dosing remains a key challenge for future research.